Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06863480 · ClinicalTrials.gov registry record · Phase 1
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
A Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06863480: Recruiting Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia, sponsored by University of Florida.
NCT06863480 is a Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia that is actively recruiting participants, run by University of Florida. The registered enrollment target is 30 participants, below the 341-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06863480, a Phase 1 study of Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
Primary Outcome
Elevation of liver transaminase (ALT, AST) is defined as \>5x upper limit of normal.
Conditions Studied
Interventions
- DRUG tocilizumab-aazg (TYENNE)
Study Locations (1)
Florida
- University of Florida Health (UF Health) - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2028-10-30 |
| Phase | Phase 1 |
What NCT06863480 shows while recruiting
NCT06863480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 341-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Aneurysmal Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which tocilizumab-aazg (TYENNE) is the first listed.
NCT06863480 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06863480 about?
NCT06863480 is a clinical study titled "Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events". In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
What is the current status of trial NCT06863480?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-02. Estimated completion is 2028-10-30.
What conditions does trial NCT06863480 study?
This clinical trial studies the following conditions: Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia.
What interventions are being tested in trial NCT06863480?
The interventions under investigation include: tocilizumab-aazg (TYENNE) (DRUG).
Who is sponsoring clinical trial NCT06863480?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06863480 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysmal Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
RECRUITING · Phase 2
-
Florida Cerebrovascular Disease Biorepository and Genomics Center
ACTIVE NOT RECRUITING
-
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
COMPLETED · Phase 3
-
Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI